Progyny price to sales ratio PGNY
Market value divided by revenue over the last twelve months, since 2020.
- Today, Nov 2, 2026
- 1.7×
- 7-year median
- 3.8×
- Against its 7-year history
- 28th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 1.0× to 14.8×
- Peer median
- 1.3×
Progyny's price to sales ratio is 1.7× as of Nov 2, 2026.
That is below its 7-year median of 3.8×, lower than on 72% of days in the last 7 years.
Over that time it ranged from 1.0× in Nov 2024 to 14.8× in Jun 2021.
The median for 10 hospital and care facility stocks of a similar size is 1.3×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.7× | 1.0× | 1.9× |
| 2025 | 1.8× | 1.3× | 1.8× |
| 2024 | 1.3× | 1.0× | 3.8× |
| 2023 | 3.4× | 2.8× | 4.7× |
| 2022 | 4.1× | 4.1× | 9.5× |
| 2021 | 9.6× | 8.9× | 14.8× |
| 2020 | 11.9× | 6.5× | 11.9× |
Against its peers
Companies in Medical - Care Facilities nearest Progyny's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| PGNYProgyny | 1.7× |
| ADUSAddus HomeCare | 1.6× |
| MDPediatrix Medical | 1.2× |
| PRVAPrivia Health | 1.2× |
| AVAHAveanna Healthcare | 1.1× |
| HCSGHealthcare Services | 0.9× |
| ARDTArdent Health | 0.3× |
| NHCNational Healthcare | 2.0× |
| PNTGPennant | 1.3× |
| USPHU S Physical Therapy | 1.6× |
| OMDAOmada Health | 3.5× |
| Peer median | 1.3× |
Where Progyny ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Progyny
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.